OncoMatch/Clinical Trials/NCT07067255
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Is NCT07067255 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GPC3 CD146 CAR-T cells for ovarian cancer.
Treatment: GPC3 CD146 CAR-T cells — This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or refractory ovarian cancer. Eligible patients will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by an infusion of autologous CD146-directed CAR-T cells (Arm A) and a subsequent infusion of autologous GPC3-directed CAR-T cells (Arm B). The Phase 1 portion will assess safety, tolerability, and dose-limiting toxicities (DLTs) to determine a recommended Phase 2 dose, while the Phase 2 portion will evaluate efficacy endpoints including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Patients will be followed for up to 36 months after CAR-T infusion to monitor long-term outcomes and adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Sarcoma
Biomarker criteria
Required: GPC3 positive expression (positive)
Required: MCAM positive expression (positive)
Disease stage
Required: Stage IV
Metastatic disease required
Ovarian Cancer Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have received and progressed on or after at least one line of platinum-based chemotherapy (or be platinum-resistant)
Cannot have received: CAR-T cell therapy or other gene-engineered T-cell therapy targeting CD146 or GPC3
Previous treatment with any CAR-T cell therapy or other gene-engineered T-cell therapy targeting CD146 or GPC3
Lab requirements
Blood counts
absolute neutrophil count (anc) above a minimum threshold, platelet count above threshold, hemoglobin above threshold (transfusion allowed)
Kidney function
creatinine clearance ≥50 ml/min or per protocol criteria
Liver function
serum ast/alt and bilirubin ≤2× upper limit of normal (unless due to liver involvement by tumor)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify